Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10485065 | Value in Health | 2012 | 9 Pages |
Abstract
Eplerenone appears more cost-effective than spironolactone for the treatment of post-MI HF. These findings, however, remain subject to important uncertainties regarding the effects of treatment on major clinical events. An adequately powered, well-conducted randomized controlled trial that directly compares spironolactone and eplerenone may be required to provide more robust evidence on the optimal management of post-MI HF. Despite these uncertainties, the use of an aldosterone antagonist was consistently demonstrated to be a highly cost-effective strategy for the management of post-MI HF in the National Health Service.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Claire PhD, Simon MSc, Paula PhD, Elisabeth PhD, Jane PhD, Sara MSc, Ameet MD, Klaus MD, Melissa MSc, Kath MSc, Nerys PhD, Stephen MSc,